Perrigo’s Record OTC Sales Tempered By Rising Costs Of Doing Business

Record OTC drug sales helped boost Perrigo's revenue 29 percent in its latest earnings period, but the rising costs of doing business dragged down margins and forced the company to lower its fiscal 2009 earnings guidance